Αρχική World News FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic... World News FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma Από Ogkologos - 26 Μαΐου, 2025 666 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The Nobel Prize winner helping us treat children’s cancers 8 Νοεμβρίου, 2022 Researchers at Purdue Create Filler That May Help Regenerate Tissue in... 9 Μαρτίου, 2021 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas 27 Ιουνίου, 2023 Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... 7 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS What to Know About Getting Access to New Cancer Advances Presented... Could virtual reality become a reality in cancer supportive care? Preparación para el fin de la emergencia de salud pública (PHE)... Women at High Risk of Breast Cancer Find it Hard to...